BeOne Medicines (NASDAQ:ONC) SVP Sells $110,265.64 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 428 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $257.63, for a total value of $110,265.64. Following the sale, the senior vice president owned 346,554 shares in the company, valued at approximately $89,282,707.02. This trade represents a 0.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The stock was sold at an average price of $270.42, for a total value of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total value of $103,159.04.
• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $311.59, for a total value of $103,447.88.

BeOne Medicines Stock Up 1.4%

NASDAQ ONC traded up $3.72 during trading hours on Monday, hitting $268.20. 351,440 shares of the company were exchanged, compared to its average volume of 258,341. The company has a 50 day moving average of $298.56 and a two-hundred day moving average of $314.03. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $239.25 and a 52-week high of $385.22. The firm has a market cap of $29.43 billion, a price-to-earnings ratio of 60.00 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The company had revenue of $1.51 billion for the quarter. Equities research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ONC. Morgan Stanley restated an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a report on Thursday, May 7th. Royal Bank Of Canada raised their target price on BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Guggenheim raised their target price on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Jefferies Financial Group lowered BeOne Medicines from a “buy” rating to a “hold” rating and cut their target price for the stock from $420.00 to $290.00 in a research report on Monday, March 16th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, BeOne Medicines presently has an average rating of “Moderate Buy” and an average target price of $390.00.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently made changes to their positions in ONC. Cetera Investment Advisers acquired a new stake in shares of BeOne Medicines during the 2nd quarter worth about $455,000. Rhumbline Advisers purchased a new position in BeOne Medicines during the 2nd quarter worth approximately $275,000. Arrowstreet Capital Limited Partnership purchased a new position in BeOne Medicines during the 2nd quarter worth approximately $505,000. Invesco Ltd. purchased a new position in BeOne Medicines during the 2nd quarter worth approximately $422,000. Finally, EverSource Wealth Advisors LLC purchased a new position in BeOne Medicines during the 2nd quarter worth approximately $68,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.